Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Osman AEG, Deininger MW. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. Blood Rev. 2021 Sep;49:100825. doi: 10.1016/j.blre.2021.100825. Epub 2021 Mar 16. Review. PubMed PMID: 33773846; PubMed Central PMCID: PMC8563059.
Yan D, Franzini A, Pomicter AD, Halverson BJ, Antelope O, Mason CC, Ahmann JM, Senina AV, Vellore NA, Jones CL, Zabriskie MS, Than H, Xiao MJ, van Scoyk A, Patel AB, Clair PM, Heaton WL, Owen SC, Andersen JL, Egbert CM, Reisz JA, D'Alessandro A, Cox JE, Gantz KC, Redwine HM, Iyer SM, Khorashad JS, Rajabi N, Olsen CA, O'Hare T, Deininger MW. SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA. Blood Cancer Discov. 2021 May;2(3):266-287. doi: 10.1158/2643-3230.BCD-20-0168. Epub 2019 Dec 2. PubMed PMID: 34027418; PubMed Central PMCID: PMC8133360.
Pomicter AD, Clair PM, Yan D, Heaton WL, Eiring AM, Anderson MB, Richards SM, Gililland J, O'Hare T, Deininger MW. Femoral Heads from Total Hip Arthroplasty as a Source of Adult Hematopoietic Cells. Acta Haematol. 2021;144(4):458-464. doi: 10.1159/000511953. Epub 2021 Jan 7. PubMed PMID: 33412552; PubMed Central PMCID: PMC8260615.
Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, O'Hare T, Deininger MW. Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia. 2020 Nov;34(11):2981-2991. doi: 10.1038/s41375-020-0858-1. Epub 2020 May 14. PubMed PMID: 32409689; PubMed Central PMCID: PMC7606260.
Than H, Pomicter AD, Yan D, Beaver LP, Eiring AM, Heaton WL, Senina A, Clair PM, Shacham S, Mason CC, Hare TO, Deininger MW. Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells. Leukemia. 2020 Jun;34(6):1679-1683. doi: 10.1038/s41375-020-0708-1. Epub 2020 Jan 24. PubMed PMID: 31980730; PubMed Central PMCID: PMC7364821.
Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH Jr, Winton EF, Parker DR, Lee H, Reister A, Schultz, Savage S, Stevens, Brockett C, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. J Clin Oncol. 2020 Apr 1;38(10):1006-1018. doi: 10.1200/JCO.19.00895. Epub 2019 Dec 27. PubMed PMID: 31880950; PubMed Central PMCID: PMC7106977.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3. Review. PubMed PMID: 32127639; PubMed Central PMCID: PMC7214240.
Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann JM, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu SN, O'Hare T, Prchal JT, Deininger MW. JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood. 2019 Dec 26;134(26):2388-2398. doi: 10.1182/blood.2019001385. PubMed PMID: 31697804; PubMed Central PMCID: PMC6933291.
Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328. PubMed PMID: 31826340; PubMed Central PMCID: PMC7724923.
Schneeweiss-Gleixner M, Byrgazov K, Stefanzl G, Berger D, Eisenwort G, Lucini CB, Herndlhofer S, Preuner S, Obrova K, Pusic P, Witzeneder N, Greiner G, Hoermann G, Sperr WR, Lion T, Deininger M, Valent P, Gleixner KV. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. EBioMedicine. 2019 Dec;50:111-121. doi: 10.1016/j.ebiom.2019.11.004. Epub 2019 Nov 21. PubMed PMID: 31761618; PubMed Central PMCID: PMC6921367.
Yan D, Pomicter AD, O'Hare T, Deininger MW. ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?. Clin Cancer Res. 2019 Nov 15;25(22):6561-6563. doi: 10.1158/1078-0432.CCR-19-2270. Epub 2019 Sep 20. PubMed PMID: 31540978; PubMed Central PMCID: PMC6858959.
Franzini A, Pomicter AD, Yan D, Khorashad JS, Tantravahi SK, Than H, Ahmann JM, O'Hare T, Deininger MW. The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. Blood Adv. 2019 Oct 22;3(20):2949-2961. doi: 10.1182/bloodadvances.2019000585. PubMed PMID: 31648319; PubMed Central PMCID: PMC6849944.
Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, Heinrich MC, Tyner JW, Rea D, Cayuela JM, Kim DW, Tognon CE, O'Hare T, Druker BJ, Deininger MW. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell. 2019 Oct 14;36(4):431-443.e5. doi: 10.1016/j.ccell.2019.08.004. Epub 2019 Sep 19. PubMed PMID: 31543464; PubMed Central PMCID: PMC6893878.
Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lübbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstöcker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica. 2019 Oct;104(10):1935-1949. doi: 10.3324/haematol.2019.222059. Epub 2019 May 2. Review. PubMed PMID: 31048353; PubMed Central PMCID: PMC6886439.
Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood. 2019 Sep 12;134(11):867-879. doi: 10.1182/blood.2019000611. Epub 2019 Jul 31. PubMed PMID: 31366621; PubMed Central PMCID: PMC6742922.
Antelope O, Vellore NA, Pomicter AD, Patel AB, Van Scoyk A, Clair PM, Deininger MW, O'Hare T. BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. Exp Hematol. 2019 Sep;77:36-40.e2. doi: 10.1016/j.exphem.2019.08.007. Epub 2019 Sep 4. PubMed PMID: 31493432; PubMed Central PMCID: PMC6803074.
Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA. Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol. 2019 Aug;37(3):240-252. doi: 10.1002/hon.2622. Epub 2019 Jun 20. Review. PubMed PMID: 31013548.
Gilreath JA, Tchertanov L, Deininger MW. Novel approaches to treating advanced systemic mastocytosis. Clin Pharmacol. 2019;11:77-92. doi: 10.2147/CPAA.S206615. eCollection 2019. Review. PubMed PMID: 31372066; PubMed Central PMCID: PMC6630092.
Patel AB, Miles RR, Deininger MW. Lysozyme nephropathy in chronic myelomonocytic leukemia. Clin Case Rep. 2019 Jun;7(6):1263-1264. doi: 10.1002/ccr3.2188. eCollection 2019 Jun. PubMed PMID: 31183108; PubMed Central PMCID: PMC6553339.
Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Crescenzo R, Mamolo C, Reisman A, Hochhaus A, Brümmendorf TH. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. J Cancer Res Clin Oncol. 2019 Jun;145(6):1589-1599. doi: 10.1007/s00432-019-02894-3. Epub 2019 Apr 15. PubMed PMID: 30989330.
Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M. Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44]. Leuk Res. 2019 Jun;81:105. doi: 10.1016/j.leukres.2019.04.006. Epub 2019 Apr 24. PubMed PMID: 31029462; PubMed Central PMCID: PMC8153734.
Patel AB, Pettijohn EM, Abedin SM, Raps E, Deininger MW. Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations. Blood Adv. 2019 Apr 9;3(7):952-955. doi: 10.1182/bloodadvances.2019032300. PubMed PMID: 30923049; PubMed Central PMCID: PMC6457233.
Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton WL, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Prchal JT, O'Hare T, Deininger MW. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. Clin Cancer Res. 2019 Apr 1;25(7):2323-2335. doi: 10.1158/1078-0432.CCR-18-0959. Epub 2018 Dec 18. PubMed PMID: 30563936; PubMed Central PMCID: PMC6445677.
Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M. Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. Leuk Res. 2019 Apr;79:38-44. doi: 10.1016/j.leukres.2019.02.012. Epub 2019 Feb 28. PubMed PMID: 30849661; PubMed Central PMCID: PMC8148985.
Shouksmith AE, Shah F, Grimard ML, Gawel JM, Raouf YS, Geletu M, Berger-Becvar A, de Araujo ED, Luchman HA, Heaton WL, Bakhshinyan D, Adile AA, Venugopal C, O'Hare T, Deininger MW, Singh SK, Konieczny SF, Weiss S, Fishel ML, Gunning PT. Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. J Med Chem. 2019 Mar 14;62(5):2651-2665. doi: 10.1021/acs.jmedchem.8b01957. Epub 2019 Mar 6. PubMed PMID: 30776234; PubMed Central PMCID: PMC7190078.
Wang J, Li L, Yang J, Clair PM, Glenn MJ, Stephens DM, Radford DC, Kosak KM, Deininger MW, Shami PJ, Kopeček J. Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine. Nanomedicine. 2019 Feb;16:217-225. doi: 10.1016/j.nano.2018.12.011. Epub 2019 Jan 9. PubMed PMID: 30639670; PubMed Central PMCID: PMC6408272.
Niyongere S, Lucas N, Zhou JM, Sansil S, Pomicter AD, Balasis ME, Robinson J, Kroeger J, Zhang Q, Zhao YL, Ball M, Komrokji R, List A, Deininger MW, Fridley BL, Santini V, Solary E, Padron E. Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia. 2019 Jan;33(1):205-216. doi: 10.1038/s41375-018-0203-0. Epub 2018 Jul 19. PubMed PMID: 30026572; PubMed Central PMCID: PMC7787307.
Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Dec;16(12):1500-1537. doi: 10.6004/jnccn.2018.0088. PubMed PMID: 30545997.
Heaton WL, Senina AV, Pomicter AD, Salama ME, Clair PM, Yan D, Bell RN, Gililland JM, Prchal JT, O'Hare T, Deininger MW. Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion. Leukemia. 2018 Nov;32(11):2399-2411. doi: 10.1038/s41375-018-0131-z. Epub 2018 Apr 18. PubMed PMID: 29749399; PubMed Central PMCID: PMC6224399.
Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17. PubMed PMID: 30333627; PubMed Central PMCID: PMC6280667.
Than H, Qiao Y, Huang X, Yan D, Khorashad JS, Pomicter AD, Kovacsovics TJ, Marth GT, O'Hare T, Deininger MW. Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective. Leukemia. 2018 Sep;32(9):2049-2054. doi: 10.1038/s41375-018-0050-z. Epub 2018 Mar 27. PubMed PMID: 29588547; PubMed Central PMCID: PMC6128729.
Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hobbs G, Jagasia M, Kantarjian HM, Maness L, Metheny L, Moore JO, Pallera A, Pancari P, Patnaik M, Purev E, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Sep;16(9):1108-1135. doi: 10.6004/jnccn.2018.0071. PubMed PMID: 30181422.
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22. PubMed PMID: 29567798; PubMed Central PMCID: PMC6071555.
Patel AB, Lange T, Pomicter AD, Conley CJ, Harrington CA, Reynolds KR, Kelley TW, O'Hare T, Deininger MW. Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib. Oncotarget. 2018 Apr 3;9(25):17889-17894. doi: 10.18632/oncotarget.24954. eCollection 2018 Apr 3. PubMed PMID: 29707154; PubMed Central PMCID: PMC5915162.
Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer. 2018 Apr 2;18(1):359. doi: 10.1186/s12885-018-4273-1. PubMed PMID: 29609532; PubMed Central PMCID: PMC5879565.
Kovacsovics TJ, Mims A, Salama ME, Pantin J, Rao N, Kosak KM, Ahorukomeye P, Glenn MJ, Deininger MWN, Boucher KM, Bavisotto LM, Gutierrez-Sanchez G, Kennedy TP, Marcus SG, Shami PJ. Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia. Blood Adv. 2018 Feb 27;2(4):381-389. doi: 10.1182/bloodadvances.2017013391. PubMed PMID: 29467192; PubMed Central PMCID: PMC5858478.
Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Miles RR, Graham JM, Hwang JY, Varley KE, Toydemir RM, Deininger MW, Raetz EA, O'Hare T. A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia. Haematologica. 2018 Feb;103(2):e87-e91. doi: 10.3324/haematol.2017.165282. Epub 2017 Dec 28. PubMed PMID: 29284681; PubMed Central PMCID: PMC5792293.
Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017 Nov 1. PubMed PMID: 29091516; PubMed Central PMCID: PMC5966023.
Tharkar-Promod S, Johnson DP, Bennett SE, Dennis EM, Banowsky BG, Jones SS, Shearstone JR, Quayle SN, Min C, Jarpe M, Mosbruger T, Pomicter AD, Miles RR, Chen WY, Bhalla KN, Zweidler-McKay PA, Shrieve DC, Deininger MW, Chandrasekharan MB, Bhaskara S. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. Leukemia. 2018 Jan;32(1):49-60. doi: 10.1038/leu.2017.174. Epub 2017 Jun 5. PubMed PMID: 28579617; PubMed Central PMCID: PMC5716937.
Qiang W, Antelope O, Zabriskie MS, Pomicter AD, Vellore NA, Szankasi P, Rea D, Cayuela JM, Kelley TW, Deininger MW, O'Hare T. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. Leukemia. 2017 Dec;31(12):2844-2847. doi: 10.1038/leu.2017.264. Epub 2017 Aug 18. PubMed PMID: 28819281; PubMed Central PMCID: PMC7566958.
Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Canc Netw. 2017 Oct;15(10):1193-1207. doi: 10.6004/jnccn.2017.0157. PubMed PMID: 28982745.
Tantravahi SK, Guthula RS, O'Hare T, Deininger MW. Minimal Residual Disease Eradication in CML: Does It Really Matter?. Curr Hematol Malig Rep. 2017 Oct;12(5):495-505. doi: 10.1007/s11899-017-0409-7. Review. PubMed PMID: 28852963.
Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, Pollyea DA, Medeiros BC, Traer E, Tognon CE, Mori M, Druker BJ, Tyner JW. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7554-E7563. doi: 10.1073/pnas.1703094114. Epub 2017 Aug 7. PubMed PMID: 28784769; PubMed Central PMCID: PMC5594650.
Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica. 2017 Sep;102(9):1519-1529. doi: 10.3324/haematol.2016.163436. Epub 2017 Jun 8. PubMed PMID: 28596283; PubMed Central PMCID: PMC5685220.
Patel AB, O'Hare T, Deininger MW. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors. Hematol Oncol Clin North Am. 2017 Aug;31(4):589-612. doi: 10.1016/j.hoc.2017.04.007. Review. PubMed PMID: 28673390; PubMed Central PMCID: PMC5505321.
Hoffmann VS, Hasford J, Deininger M, Cortes J, Baccarani M, Hehlmann R. Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. J Cancer Res Clin Oncol. 2017 Jul;143(7):1311-1318. doi: 10.1007/s00432-017-2385-7. Epub 2017 Mar 8. Review. PubMed PMID: 28275866.
Patel AB, Wilds BW, Deininger MW. Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?. Expert Rev Hematol. 2017 Jul;10(7):659-674. doi: 10.1080/17474086.2017.1330144. Epub 2017 May 22. Review. PubMed PMID: 28511567.
Deininger MWN, Tyner JW, Solary E. Turning the tide in myelodysplastic/myeloproliferative neoplasms. Nat Rev Cancer. 2017 Jun 23;17(7):425-440. doi: 10.1038/nrc.2017.40. Review. PubMed PMID: 28642604.
Wallace JA, Kagele DA, Eiring AM, Kim CN, Hu R, Runtsch MC, Alexander M, Huffaker TB, Lee SH, Patel AB, Mosbruger TL, Voth WP, Rao DS, Miles RR, Round JL, Deininger MW, O'Connell RM. miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response. Blood. 2017 Jun 8;129(23):3074-3086. doi: 10.1182/blood-2016-09-740209. Epub 2017 Apr 21. PubMed PMID: 28432220; PubMed Central PMCID: PMC5465836.
Carey A, Edwards DK 5th, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A. Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. Cell Rep. 2017 Mar 28;18(13):3204-3218. doi: 10.1016/j.celrep.2017.03.018. PubMed PMID: 28355571; PubMed Central PMCID: PMC5437102.
What would you like to do?